Tag: GlobeNewswire

CEO Dmitry Kroshka Provides Updates on Phunware 2.0, Including Recently Launched AI Concierge, Recently Announced Itinerary Planner, and its AI-Forward Development Process

Highlights Go-Forward Plan, Meaningful Milestones, and Growth Priorities

AUSTIN, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), a provider of AI-enabled guest intelligence software to operators of hotels, resorts, and other large, complex properties, today issued a letter to shareholders from its Chief Executive Officer, Dmitry Kroshka.

Dear Phunware Shareholders,

My name is Dmitry Kroshka, and just over five months ago, I became CEO of Phunware. This is my first letter to you. I want to tell you plainly where we stand and where we are going, how we intend to get there, and how you can hold us accountable.

CEO Vision

Where we are going. We intend to complete the evolution of Phunware from a wayfinding and enterprise app developer to an AI enabled B2B intelligence platform capable of scale through our Phunware 2.0 strategy, starting with hospitality and healthcare customers. We gained the trust of major customers by installing IoT infrastructure for internal mapping and building world-class mobile applications across multiple properties. The groundwork has been laid. Now we will build on it.

Why we win. We give operators what they want most: the ability to reach guests in the moment, understand what guests are doing and want to do, and turn foot traffic into incremental revenue. Our technology is installed inside marquee brands’ properties, and our contracts run for years. We are already on site, trusted, and seeing how and when guests move through a property in real time. Our Sales and Marketing efforts have established a robust pipeline of multi-property ownership groups who are eager to try our technology. This is a significant shift toward scaled, multi-property transactions, rather than single-property deals.

What we carry forward. Phunware was early to mobile. We have moved just as fast to AI, and are building it into our products, our user experience, and the way we run Phunware. AI is going to change how hospitality and healthcare companies engage with their guests, patients, residents, and visitors from end to end. Our customers need a partner with a real stake in the outcome to lead them through that change. We intend to be that partner.

What we own. Since going public, Phunware has been through several business cycles, and at times it has struggled. However, over the past year we assembled a team of new leaders and advisors around product, sales, and marketing, and we believe the right team is now in place to complete and deliver Phunware 2.0.

In this letter and in the months ahead, I’ll lay out more details on our progress for Phunware 2.0 and share meaningful milestones. Thank you for your continued support.

My Background

I joined Phunware as an executive consultant in October 2025, bringing experience from previous travel and hospitality projects. In 2013, I ran a new omnichannel media business at Responsys, continuing that work at Oracle after it acquired Responsys. We combined first-party data with third-party intent signals and built one of the first platforms that enabled personalized, omnichannel loyalty marketing at scale.

Phunware presents a similar data opportunity. We already capture proprietary location-based data at marquee properties through beacons, GPS, and Wi-Fi. Connected to a property’s marketing and technology stack, that data becomes an intent graph: a picture of what guests do and are doing, want and are likely to want, before they arrive, while they are on site, and after they leave the property. Few companies have the on-property infrastructure, software, AI expertise, and customer relationships to build and capitalize on this. Phunware does.

What We Are Building

Phunware 2.0 is the reset of Phunware from an enterprise mobile app development company to a data and intelligence platform company. At its core is our Guest Intelligence Platform. Our vision is simple:

We help the people who run complex physical properties understand what is happening on their properties, anticipate guests’ needs and preferences, and act on them.

For guests, patients, residents, and visitors, this means easier navigation, more relevant recommendations, getting help, and better access to services and experiences while they are on-property. For operators, it means capturing spend they would otherwise miss or fail to attribute properly, like a poolside cabana or a spa booking, reducing no-shows, and making more efficient use of staff time. For operations, marketing, and IT teams, it means location-based data, engagement data, robust analytics, and recommendations that work alongside the systems they already run.

Software companies learned long ago that customers who adopt more of a product get better outcomes. The same is true for a physical property: guests who use more of what a resort offers are happier and spend more time and money on-property.

Nearly every hospitality technology company is talking about AI, but most of the AI deployments we see today are transactional and built to push a sale rather than anticipate a need. By combining real-time location intelligence with guest behavior and engagement data, Phunware can deliver personalized recommendations when and where they are the most relevant to act in the moment. Every property to which we deploy Phunware modules adds various categories of data to an intent graph, and that proprietary dataset, with measurable impact, is our moat.

Since January we have:

• Launched AI Concierge, connected to our location-based Mobile Engagement hospitality solution.
• Announced Itinerary Planner in May and demonstrated it in June; it is in beta now.
• Announced a new operator console with revamped location-aware analytics and self-serve reporting, being demonstrated to prospective customers starting next week.
• Commenced building an AI recommendation engine and guest profile enrichment.

Each of these is a module and part of our full platform. North America has roughly 3,000 to 4,000 spatially complex resorts¹, the market our original platform was built for. Because Itinerary Planner, Operator Console, AI Concierge, and Mobile Engagement now work on their own, we can deliver guest intelligence to almost any property, regardless of who built its app, website, or kiosk. That expands our hospitality market to roughly 30,000 to 40,000 3-star and above properties in the US alone.

Our technology stack and modular product build is designed to scale to other complex domains, including healthcare, where 90% of the technology is shared with our hospitality offering. Leveraging on the guest experience, our healthcare products today guide patients through complex hospital systems, like NY’s Mount Sinai and Virginia’s VHC Health. Our latest release is focusing on reducing late and missed appointments, which presents major opportunities to reduce revenue shrinkage. Our technology also takes advantage of multiple related data streams, such as traffic and weather patterns, to help inform our users. We are currently working to simplify and expand our integrations and relationship with a dominant healthcare records platform used by almost 50% of US hospitals, which will allow us to enable our technology inside their existing patient portals.

Achievements Year to Date

The Board backed us to move fast. Here is a snapshot of our achievements in 2026 so far:

Quarter	What we did	Why or the result
Q1	Launched AI Concierge	Out of beta at one of the largest resorts in the Caribbean.
	Began revamp of existing platform	Location-Aware-Analytics, anonymized tracking, accessibility for Healthcare, and 30+ other feature improvements.
	Reset marketing leadership	Brought in a new team that rebuilt content marketing, qualified lead generation, and reset our overall GTM strategy, resulting in 10x qualified lead flows over last year.
	First AI Concierge results	Adoption at the customer launch property reached 70% of app users, and guest question volume was 40% above plan.
Q2	Enhanced executive leadership with Aaron Burcell, Michael Crooks, and Aaron Holloway as strategic advisors	Burcell is a former AI-forward Marketing and Operations executive, managing and accelerating our marketing; Crooks is a former data scientist and PwC Partner for Hospitality, building our channel strategy and advising on hospitality operations; Holloway is a former product leader in healthcare data, supporting our build-out of modular products with multi-ICP (Ideal Customer Profile, e.g., the specific prospects we’re targeting) applications.
	Engaged Build Something Product Group and Michael Cerdá to facilitate development and production of platform and products	Accelerated platform and product development, production, and strategy with experienced, AI-forward teams working alongside Phunware internal teams as combined unit.
	Announced and demonstrated Itinerary Planner	Itinerary planner, in conjunction with Mobile Engagement and AI Concierge, allows guests to preplan their trip, makes suggestions for plans and when plans change, and captures guest preferences before and during their stay.
	Hired Brent McMahan, Senior Director of Sales; launched new conference program schedule with HITEC	McMahan brings 15+ years in hospitality tech sales. HITEC in San Antonio produced 150+ leads and 25 meetings.
Q3	Hired Nick Farrell, SVP of Sales; working on a major Healthcare portal integration (approval pending)	Farrell brings 20+ years in hospitality tech sales. Phunware is building the necessary foundation for a productive long-term Healthcare portal relationship.
	Rapid scaling of marketing qualified lead generation	Marketing & Sales facilitated nearly 300 leads and 50+ meetings since June 2026.
	Announced Operator Console; began Itinerary Planner betas; AI Concierge expansion; kicked off new healthcare initiative	Operator Console is being demonstrated to prospects and customers in early November. In conversations with four major flags and ownership groups for 2.0. AI Concierge expanding to additional properties in Q4, now part of our modular offering. Healthcare is being expanded to optimize appointment and check-in flows; beta arriving Q1.

Today, our experienced, combined leadership team runs product, marketing, sales, and revenue operations as an integrated unit, tracking performance at every stage of the funnel.

Our product teams are centralized under Michael Cerdá, who helped build Facebook’s News Feed, Marcus by Goldman Sachs, Disney+, and Univision’s streaming services. His BSPG team has scaled algorithmic products to more than a billion users and works with our internal teams to implement AI-forward development methods to everything we ship.

Our sales team is centralized under Nick Farrell, our new SVP of Sales. Nick brings 20 years of hospitality tech sales, and comes from IDEAS and EXPEDIA. Marketing is consolidated under Aaron Burcell, who has led marketing and operations teams at Silicon Valley startups and Goldman Sachs.

Where We Stand

• We have moved past wayfinding, and are in discussions with major flags for the 2.0 platform, with consumer-facing components delivered as modules within their existing system.
• We commenced implementation of increased pricing adjustments for our platform and products.
• We have momentum in healthcare as discussed above.
• We wound down our advertising business to keep focus on core Phunware 2.0.

How We Build

We have also changed how we build. This year we moved product and engineering to an AI-forward development process. Our teams now use AI tools at each stage of the work, with experienced engineers reviewing what ships. The effect shows in our pace. Itinerary Planner went from announcement in May to working demonstration in June and into beta at properties in September. The Operator Console, the AI recommendation engine, and guest profile enrichment are being built in the same way.

A different way of building calls for a different type of team. We reorganized our internal teams to match: smaller teams, fewer layers, and senior people who own a product from concept to release. Our teams work alongside Michael Cerdá and his BSPG team, which has a force multiplier effect for Phunware and adds senior product and engineering capacity as we need it.

For shareholders, the result is more and better product for each dollar we spend on development. We will keep matching the size and shape of the teams to the strategy and work.

Capital Allocation

Investment Approach. Phunware’s balance sheet is healthy, and we have ample liquidity and carry no debt. That gives us more freedom to invest in growth, and we intend to do it with discipline. Every dollar allocated to investment will be held to the same standard: it must accelerate scale and deliver revenue with our ideal customer profiles (ICPs), operators of large, complex properties in hospitality and healthcare. We view every dollar on our balance sheet as shareholder capital, and we deploy capital responsibly behind initiatives we believe will generate attractive risk-adjusted returns.

Priority One: Organic Growth. Organic growth comes first. That means building out the Phunware 2.0 platform and its modules as we complete our shift from mobile apps to a platform model, and strengthening sales and marketing as we move our go-to-market focus from individual properties to property ownership groups, hospitality flags, and healthcare systems. This strategic pivot requires us to retool and enhance our teams, but our growth plan does not call for a material increase in headcount.

Legacy Tech. We already paid for the wayfinding technology that anchors our competitive advantage in location-based services today. We will spread that investment across more customers, more sectors, and new revenue streams.

Our fixed cost base remains large relative to revenue, and we continue to operate at a loss. We expect to reverse this by focusing on revenue and scale, both organically and through strategic M&A.

Priority Two: Strategic M&A. Acquisitions come second, pursued selectively, and only where a deal gets Phunware 2.0 to market faster or better than we could accomplish on our own. We will evaluate each opportunity on whether:

• It serves our ICPs and extends or complements the platform or the products we sell.
• It accelerates revenue growth through cross-sell or upsell: our modules into its customers, or its products into ours.
• It helps our products scale, adding properties and data to the platform.
• It is one we can purchase, maintain, and grow responsibly.
• It is accretive to our bottom line.

We will pass on opportunities that do not meet these tests. When we commit capital to an acquisition, we will explain what we bought and how and why it fits within our Phunware 2.0 strategy. Capital allocation decisions are among the most important decisions management and the Board can make, and we will treat them that way.

Active Board Involvement

I want to recognize our Board of Directors for the considerable time, experience, and support they have brought to Phunware 2.0. Since I became CEO, the Board has been closely engaged in the work described in this letter, continuously reviewing, testing, and sharpening our strategy, and keeping us focused on building long-term value for shareholders.

Our Board will continue to play an active role as we move from planning to executing Phunware 2.0. Our directors bring deep operating experiences, financial and business acumen, investment and capital markets expertise, broad leadership networks, and perspectives across disciplines. All of this experience strengthens our ability to pursue the market opportunity, deliver on our product roadmap, and stay disciplined on the path ahead.

How We Will Communicate

On communications, our rules are simple: we will announce platform modules and functionalities and products when they are real. We build first, announce when we can demo, and launch commercially when customers are live. We will continue to be specific, consistent, and transparent with our communications to shareholders going forward.

Thank You

We are grateful to our shareholders for your patience and support; and we are grateful to our customers whose feedback and partnership shape everything we build. We welcome your engagement with Phunware.

While we are early and there is a lot left for Phunware to prove, we have a clear strategy, a team built to execute it, and early customer evidence that it works. I look forward to reporting our progress to you over the coming months.

Sincerely,

Dmitry Kroshka
Chief Executive Officer

About Phunware

Phunware, Inc. (NASDAQ: PHUN) is an enterprise software company specializing in mobile app solutions for hospitality, healthcare, and other large property related customers, with integrated intelligent capabilities. We provide businesses with the tools to create, implement, and manage custom mobile applications, analytics, and location-based services. Phunware is transforming mobile engagement by delivering scalable, personalized, and data-driven mobile app experiences.

Phunware’s mission is to achieve unparalleled connectivity and monetization through the widespread adoption of Phunware mobile technologies, leveraging brands, consumers, partners, and market participants. Phunware is poised to expand its software products and services audience through new generative AI products and product enhancements which are in development, utilize and monetize its patents and other intellectual property, and focus on serving its enterprise customers and partners.

For more information on Phunware, please visit www.phunware.com.

Safe Harbor / Forward-Looking Statements

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans, our objectives for future operations, the development and commercial rollout of our Product 2.0 strategy and Guest Intelligence Platform, the performance and adoption of our AI Concierge, AI Itinerary Builder, and Location-Aware Data Layer capabilities, the expansion of our product offering into adjacent end markets, and the timing of upcoming investor and industry events, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” and similar expressions are intended to identify forward-looking statements.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. These forward-looking statements involve risks, uncertainties, and other assumptions that may cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in our filings with the SEC. We undertake no obligation to update any forward-looking statements.

By their nature, forward-looking statements involve risks and uncertainties. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those expressed or implied by these forward-looking statements.

Investor Relations Contact:
Chris Tyson, Executive Vice President
MZ Group – MZ North America
949-491-8235
PHUN@mzgroup.us
www.mzgroup.us

¹ Wu, Chantal. “Resorts deliver strongest hotel room revenue gains across US location types.” CoStar Analytics, July 10, 2026.

Persons who received initial merger consideration will receive the final issuance, bringing their total consideration to 7,221,468 FLYX shares, including the 5,676,893 shares already issued

LAS VEGAS, Oct. 29, 2026 (GLOBE NEWSWIRE) — Jet.AI Inc. (NASDAQ: JTAI) (“Jet.AI” or the “Company”), an emerging provider of high-performance GPU infrastructure and AI cloud services, today announced the final determination of the post-closing purchase price associated with its previously announced and closed transaction with flyExclusive, Inc. (“flyExclusive”). As a result of this determination, flyExclusive will issue an aggregate of 1,544,575 shares of its Class A common stock to the same persons who received the transaction consideration. No action is required and the additional shares of flyExclusive Class A common stock are expected to be distributed on or about October 30, 2026.

As previously described, persons eligible to receive consideration in connection with the transaction initially received an aggregate of 5,676,893 shares of flyExclusive’s Class A common stock. This represented approximately 80% of the consideration to which those persons are entitled. After determining the final post-closing purchase price associated with the transaction, flyExclusive will release 1,419,224 shares of its Class A common stock held in reserve and issue an additional 125,351 shares of its Class A common stock to the same persons who received the initial consideration.

This represents a significant milestone for Jet.AI as it pivots from its historical operations to providing high-performance GPU infrastructure and AI cloud services. The Company intends to explore additional strategic transactions and business opportunities that provide stockholder value and support its new focus.

About Jet.AI Inc.
Jet.AI Inc. (NASDAQ: JTAI) is a technology-driven company focused on deploying artificial intelligence tools and high-performance GPU infrastructure to enhance decision-making, efficiency, and performance across complex systems. The Company is listed on the NASDAQ Capital Market under the ticker symbol “JTAI.” To learn more, visit www.jet.ai.

Additional Information and Where to Find It
In connection with the transactions contemplated by the Amended and Restated Agreement and Plan of Merger and Reorganization, dated May 6, 2025, between Jet.AI, flyExclusive, FlyX Merger Sub, Inc., and Jet.AI SpinCo, Inc. (as amended, the “Merger Agreement”), flyExclusive has filed a Registration Statement on Form S-4 (File No. 333-284960) (as amended, the “Registration Statement”) to register the shares of flyExclusive common stock that were issued in connection with the merger transaction. The Registration Statement was declared effective on April 30, 2026. Jet.AI and flyExclusive filed a definitive proxy statement and final prospectus, respectively (together, the “Proxy Statement/Prospectus”), with the SEC on May 4, 2026 and they each may file with the SEC other relevant documents concerning the proposed transactions. This communication is not a substitute for the Registration Statement, the Proxy Statement/Prospectus, or any other document that the parties have filed or will file with the SEC, or send to stockholders, in connection with the proposed transactions.

This communication is not a substitute for the Registration Statement, the Proxy Statement, or any other document that the parties have filed or will file with the SEC, or send to stockholders, in connection with the proposed Transactions. Copies of the Registration Statement, Proxy Statement/Prospectus, as well as other filings containing information about the Company, may be obtained, free of charge, at the SEC’s website at www.sec.gov. You can also obtain these documents, free of charge, from the Company by accessing the Company’s website at investors.jet.ai, by directing a request to the Company at 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV 89135, Attention: Board Secretary, or by phone at (702) 747-4000. The information on the Company’s website is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

No Offer or Solicitation
This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The proposed transactions are expected to be implemented solely pursuant to the legally binding definitive agreement, which contains the material terms and conditions of the proposed transactions. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.

Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, with respect to the products and services offered by Jet.AI and the markets in which it operates, Jet.AI’s projected future results, and Jet.AI’s perception of market conditions, including the expected timing of the issuance of merger consideration and the future business strategy of Jet.AI. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our Company, our industry, our beliefs and our assumptions. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results, including the failure to satisfy closing conditions and broader market conditions. As a result, caution must be exercised in relying on forward-looking statements, which speak only as of the date they were made. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements can be found in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and Jet.AI assumes no obligation and does not intend to update or revise these forward-looking statements, whether because of new information, future events, or otherwise, except as provided by law.

Investor Relations Contact
Gateway Group, Inc.
949-574-3860
Jet.AI@gateway-grp.com

PLANTATION, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (Nasdaq: AENT), a scaled entertainment commerce and collectibles platform serving content owners, brands, retailers and fans across music, movies, gaming, licensed merchandise and collectibles, with proprietary brands, authentication technology and reach across more than 35,000 retail and e-commerce storefronts, will hold a conference call on Thursday, November 12, at 4:30 p.m. Eastern Time to discuss its results for the first quarter of fiscal year 2027 ended September 30, 2026. A press release detailing these results will be issued prior to the call.

Alliance Entertainment Chief Executive Officer Jeff Walker, Chief Financial Officer Amanda Gnecco, and Executive Chairman Bruce Ogilvie will host the conference call, which will be followed by a question-and-answer session. A presentation will accompany the call and can be viewed during the webcast or accessed via the investor relations section of the Company’s website here.

To access the call, please use the following information:

Date:	Thursday, November 12, 2026
Time:	4:30 p.m. Eastern Time, 1:30 p.m. Pacific Time
Toll-free dial-in number:	1-844-825-9789
International dial-in number:	1-412-317-5180
Conference ID:	10213070

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact RedChip Companies at 1-407-644-4256.

The conference call will be broadcast live and available for replay at https://viavid.webcasts.com/starthere.jsp?ei=1781348&tp_key=9221210ff0 and via the investor relations section of the Company’s website here.

A telephone replay of the call will be available approximately three hours after the call concludes and can be accessed through December 12, 2026, using the following information:

Toll-free replay number:	1-844-512-2921
International replay number:	1-412-317-6671
Replay ID:	10213070

About Alliance Entertainment

Alliance Entertainment (NASDAQ: AENT) is a premier distributor and fulfillment partner for the entertainment and pop culture collectibles industry. With more than 340,000 unique in-stock SKUs – including over 57,300 exclusive titles across compact discs, vinyl LPs, DVDs, Blu-rays, and video games – Alliance offers the largest selection of physical media in the market. Our vast catalog also includes licensed merchandise, toys, retro gaming products, and collectibles, serving over 35,000 retail locations and powering e-commerce fulfillment for leading retailers. Alliance also owns and operates proprietary collectibles brands, including Handmade by Robots™, a stylized vinyl figure line featuring licensed characters from leading entertainment franchises, and Alliance Authentic™, a premium platform for authentic, certified, and individually numbered entertainment collectibles. In addition, Alliance operates Endstate Authentic, a dedicated NFC-enabled authentication and digital product identity platform supporting authenticated collectibles, resale, and brand protection. Leveraging decades of operational expertise, exclusive sourcing relationships, and a capital-light, scalable infrastructure, Alliance connects fans and collectors to the products, franchises, and experiences they value across formats and generations. For more information, visit www.aent.com.

For investor inquiries, please contact:

Dave Gentry
RedChip Companies, Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
AENT@redchip.com

STS’ long-standing radiological security partnership with NNSA/Y-12 advances U.S. national security objectives while helping preserve critical medical capabilities for international partners

New York, N.Y., Oct. 29, 2026 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear micro modular reactor and technology company developing microreactors, nuclear fuel cycle capabilities and nuclear transportation solutions, alongside Secured Transportation Services (STS), a wholly owned subsidiary, today announced its role in the successful removal and secure transportation of a vulnerable cesium-137 (Cs-137) radioactive source from the Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM) in Manaus, Brazil.

The September 2, 2026 operation was conducted in support of the U.S. Department of Energy’s National Nuclear Security Administration’s (NNSA) Office of Radiological Security (ORS) and managed by the Y-12 National Security Complex (Y-12). STS served as the lead subcontractor responsible for execution of the planning, logistics and removal activities, working closely with Y-12, Brazilian radiological experts, regulatory authorities, transportation providers, security personnel, and other project partners.

The project represents the latest achievement in a long-standing effort to reduce the security risks associated with high-activity radioactive sources while ensuring that important medical capabilities remain available to the communities that depend on them. HEMOAM had historically relied on a Gammacell 3000 blood irradiator containing a Cs-137 radioactive source. Through NNSA’s Alternative Technologies initiative, the facility transitioned to an X-ray blood irradiation system that allows it to maintain critical blood irradiation capabilities without continued reliance on the high-activity radioactive source.

“This project represents exactly what can be accomplished when national security expertise, technical capability and strong international partnerships come together around a shared mission,” said Roy A. Boyd II, President of Secured Transportation Services. “For STS, the mission extends beyond safely moving radioactive material. It is about applying decades of specialized experience to help the United States and our international partners reduce radiological risk while ensuring that essential medical capabilities remain available to the people who depend on them.”

The Manaus operation required extensive planning and coordination to safely remove the source from a working medical facility and transport it across one of Brazil’s most geographically challenging regions. The source was transported by aircraft out of the remote Manaus region to an area with an established road network, where it was transferred to ground transportation for the final leg of its journey to a secure storage facility.

Following removal, the Cs-137 source was secured in a certified Type B(U) shipping container for transport. Under the oversight of Brazil’s Autoridade Nacional de Segurança Nuclear (ANSN), STS and Y-12 personnel worked with Brazilian partners to maintain positive control of the source and continuity of custody throughout the entire operation.

The HEMOAM operation marks the eighth radioactive-source removal completed in Brazil through this series of NNSA-ORS activities since 2023. Across these missions, Y-12 has managed the removal operations, with STS supporting preplanning, specialized field execution, and transportation in coordination with Brazilian experts and authorities.

“Successful projects like this are built over years, not days,” Boyd added. “They depend on trusted relationships, disciplined planning, and people who understand that safety and security cannot be compromised. We are proud of the STS team and proud to continue supporting Y-12 and NNSA in a mission that strengthens the security of the United States while providing meaningful benefits to our international partners.”

The Brazil program demonstrates the broader value of U.S. leadership in radiological security. By helping partner nations transition away from vulnerable high-activity radioactive sources where appropriate, these efforts reduce the potential for radioactive material to be lost, stolen, or used for malicious purposes while supporting the continued availability of technologies essential to healthcare and other peaceful applications.

For STS, the successful Manaus operation also reflects more than two decades of experience supporting complex nuclear and radiological transportation missions where safety, security, regulatory compliance, and operational execution are paramount.

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across three primary business lines: (i) cutting edge microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation..

Led by a world-class nuclear engineering team, NANO Nuclear’s flagship microreactor under development is the proprietary KRONOS MMR^™ Energy System, a stationary high-temperature gas-cooled reactor that’s advancing through the formal U.S. Nuclear Regulatory Commission (NRC) licensing process following the University of Illinois Urbana-Champaign’s construction permit application submission for the deployment of the microreactor at the university.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. STS provides specialized transportation, logistics, project management, and technical services supporting the nuclear and radiological industries. STS brings decades of experience executing complex missions involving radioactive and other sensitive materials, with an emphasis on safety, security, regulatory compliance, and mission assurance.

Through its work with U.S. government agencies, national security partners, commercial organizations and international stakeholders, STS supports the safe and secure movement and management of nuclear and radiological materials in furtherance of U.S. national security, nonproliferation, and peaceful-use objectives.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

For more corporate information please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:
Email: IR@NANONuclearEnergy.com
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:
NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward Looking Statements

This news release and statements of NANO Nuclear’s management and collaborators in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “explore”, “plans”, “aim”, “goal”, “believes”, “potential”, “future”, “will”, “should”, “could”, “would” or “may” or derivations of these words and other words of similar meaning about the future. In this press release, forward-looking statements include those relating to STS’ specialized nuclear transportation capabilities, STS’ customers and contacts, and their potential contribution to NANO Nuclear’s overall strategy and results of operations. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to: (i) risks related to our U.S. Department of Energy (“DOE”), U.S. Nuclear Regulatory Commission (“NRC”), Canadian Nuclear Safety Commission (“CNSC”) or related state or other U.S. or non-U.S. nuclear licensing submissions; (ii) risks related to the development of new or advanced technology and the acquisition or integration of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues, the development of competitive technology and the ability to generate revenue from acquired or development businesses and technologies; (iii) our ability to obtain and maintain key vendor, technology, project, financing and customer relationships and the significant funding necessary to execute on our business plan; (iv) uncertainty regarding our ability to technologically develop, license, manufacture and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever; (v) risks related to government regulation, policy, public procurement, export controls, supply-chain requirements and licensing requirements; and (vi) similar risks and uncertainties associated with operating a developing business in a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial results will be issued on the morning of Thursday, November 5, 2026. Management will host a conference call and webcast at 08:30 AM ET to discuss the results and provide business updates.

To access the live conference call, participants may register here.

Conference Details:

Conference Date: Thursday, November 5, 2026
Conference Time: 08:30 AM ET
U.S. Dial-in: 1-877-704-4453
International Dial-in: 1-201-389-0920
Conference ID: 13762793
Conference Call Name: SAB BIO Q3 2026 Earnings Call

Following the conference call, a replay of the audio webcast will be available under the Investors & Media section of the Company’s website at www.sab.bio.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is being evaluated in two clinical trials: the registrational Phase 2b SAFEGUARD study for those newly diagnosed with Stage 3 T1D and the investigator-led Phase 3 PRISE-hATG study for people up to two years following a Stage 3 T1D diagnosis. For more information, visit www.sab.bio.

CONTACTS
Investor Relations:
Christine Ryan
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

TOKYO, Japan, Oct. 29, 2026 (GLOBE NEWSWIRE) — CTW (Nasdaq: CTW) (“CTW” or “the Company”), a leading game platform company providing global access to web-based games through its flagship platform, G123.jp, today announced that its leadership will participate in the BMO Capital Markets Technology and Innovation Leaders Conference on November 12, 2026.

BMO Capital Markets Technology and Innovation Leaders Conference

Date: November 12, 2026
Location: InterContinental New York Barclay – 111 East 48^th Street, New York, NY

CTW’s participation follows its Nasdaq listing in August 2025 and the opening of its first North American office at One World Trade Center in New York City in February 2026. These milestones reflect the Company’s continued efforts to strengthen its presence in the U.S. capital markets and expand engagement with the North American investment community.

The conference will provide an opportunity for CTW to discuss its differentiated business model, portfolio of licensed anime and manga intellectual property, operating execution, user acquisition strategy and long-term growth priorities. CTW believes that consistent, transparent engagement with the investment community is an important element of building market awareness and broadening its institutional shareholder base over time.

Investors attending the conference who are interested in meeting with CTW should contact their BMO Capital Markets representative or CTW’s investor relations team at investor@ctw.inc.

About CTW

CTW is a leading game platform company providing global access to web-based, free-to-play games inspired by popular Japanese anime IP, including So I’m a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World’s Strongest – Rebellion Soul, and Queen’s Blade Limit Break. CTW delivers these games through its globally accessible flagship platform, G123.jp, which has accumulated paying users in over 200 countries since its 2018 launch. Founded in Tokyo in 2013, CTW partners with anime and manga IP holders to bring officially licensed titles to players around the world with no downloads or account registration required.

For more information, visit www.ctw.inc or G123.jp.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets,” “guidance” and similar statements. CTW may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about CTW’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: CTW’s growth strategies; its future business development, results of operations and financial condition; its ability to distribute successful and engaging games with high “playability” on its platform; its ability to efficiently attract and retain end-users who come to play and make in-game purchases; its ability to achieve positive return on investment on user acquisition efforts; its ability to establish and maintain relationships with game developers; governmental policies and regulations relating to CTW’s industry; and general economic and business conditions globally and in Japan and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks, uncertainties or factors is included in CTW’s filings with the SEC. All information provided in this press release is as of the date of this press release, and CTW undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Contacts

Media Contact:
CTW Press Team
corpcomm@ctw.inc

Investor Relations Contact:
Patrick Federle | Head of Investor Relations
investor@ctw.inc

• Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ET
• ALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy Data from the Phase 1 RESOLUTION Study Scheduled for November 9, 2026 at 6:00 a.m. PT/9:00 a.m. ET
• Preliminary Data from the Phase 1 RESOLUTION Trial will also be Presented at American College of Rheumatology (ACR) Convergence 2026

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced two November investor events highlighting third quarter 2026 results and the first clinical update from its ALLO-329 autoimmune disease program.

Q3 2026 Financial Results and General Business Updates
The Company will report third quarter 2026 financial results and provide a business update on November 5, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

• Listen-Only Webcast of the Conference Call
  The listen-only webcast will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company’s website for approximately 30 days.
• Conference Call Registration for Questions
  If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.

ALLO-329: Autoimmune Disease Program Update from ACR Convergence
The Company will also host a webinar on Monday, November 9, 2026, at 6:00 a.m. PT/9:00 a.m. ET to review preliminary safety and efficacy data from the ongoing Phase 1 RESOLUTION study of ALLO-329 in adults with autoimmune diseases, including lupus, myositis and scleroderma. The webinar will precede the poster presentation of the first clinical results later that day at the American College of Rheumatology’s (ACR) annual meeting, ACR Convergence.

ALLO-329 is an investigational, next-generation off-the-shelf allogeneic CAR T designed to target both CD19 and CD70. It incorporates Allogene’s proprietary Dagger^® technology, which is designed to enhance the expansion and persistence of allogeneic CAR T cells while potentially reducing or eliminating the need for conventional cytotoxic lymphodepletion.

• Listen-Only Version of the Webinar
  The listen-only webinar will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company’s website for approximately 30 days.
• Webinar Registration for Questions
  If you would like the option to ask a question on the webinar, please use this link to register. Upon registering for the webinar, you will receive a personal PIN to access the call.

ACR Poster Presentations Details:

• Session: Systemic Sclerosis & Related Disorders – Treatment Poster Session B
• Title: Preliminary Safety and Efficacy Results from a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T-Cell Therapy for Autoimmune Disease
• Presenting Author: Vivek Nagaraja, MD, FACR, Mayo Clinic Arizona
• Date/Time: Monday, November 9, 2026, 10:30 a.m.-12:30 p.m. ET

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the heading “Risk Factors” in its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings that Allogene may make from time to time with the SEC. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

Company to Host Conference Call and Webcast on November 12, 2026, at 8:30 a.m. ET

FORT WORTH, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) — Yesway, Inc. (“Yesway” or the “Company”) (Nasdaq: YSWY), one of the fastest-growing convenience store operators in the United States, today announced that it will issue its financial results for the third quarter ended September 30, 2026, before market open on Thursday, November 12, 2026. The Company will host a conference call and webcast to discuss the results that same day at 8:30 a.m. ET.

Webcast Details
A live webcast of the conference call will be available on the investor relations section of the Company’s website or by clicking on the webcast link here.

An online archive of the webcast will be available on the Company’s website for one year following the call.

About Yesway
Established in 2015 and headquartered in Fort Worth, TX, Yesway is an award-winning convenience store operator with approximately 420 stores across eight states in the Midwest and Southwest. Yesway is renowned for its iconic foodservice offerings, diverse grocery selections, and private-label products, including the famous Allsup’s deep-fried burrito. Through strategic acquisitions, the development and opening of more than 90 stores over the past several years, and a steadfast commitment to customer satisfaction and community engagement, Yesway continues to cement its position as one of the leading convenience retailers in the United States.

Investor Contact:
IR@yesway.com

Media Contact:
Erin Vadala
evadala@boltpr.com

Company Reports 500+ U.S. Leads, Expanding Healthcare Network Relationships, Federal Market Access, International Distribution and 300+ Issued and Pending Patents Worldwide

Just 2% Penetration of Estimated U.S. Epidural Procedure Market Represents $33 Million in Potential Annual Disposable Revenue

Medical Segment Revenue Increased 200%+ in Q2 2026 as Company Advances Commercial Expansion and Recurring Revenue Strategy

ROSELAND, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE American: MLSS), a medical technology company specializing in advanced computerized injection and drug-delivery technologies, today provided a comprehensive commercial update highlighting significant progress in expanding its CompuFlo^® Epidural System across U.S. and international markets.

Milestone believes its proprietary Dynamic Pressure Sensing^® technology addresses a substantial opportunity within an estimated 30 million-plus annual epidural procedures globally, including more than 11 million in the United States.

At just 2% penetration of the estimated U.S. procedure market, approximately 220,000 annual procedures would represent $33 million in potential annual disposable revenue, assuming a $150 selling price per procedure. This illustrative opportunity excludes equipment sales, international markets and potential future medical applications. It is not a revenue projection and assumes clinical eligibility, physician adoption and disposable purchasing.

With an expanded commercial organization, growing physician pipeline, established reimbursement pathways, international distribution and a substantial global patent portfolio, Milestone believes it is positioned to pursue a significantly larger share of this market.

Commercial Expansion and Recent Highlights

• 200%+ Medical Revenue Growth: Medical segment revenue increased 200%+ year-over-year in the second quarter of 2026, demonstrating early commercial momentum.
• 500+ U.S. Commercial Leads: Expanding physician and institutional pipeline generated through targeted sales, digital marketing, medical conferences, physician referrals and clinical outreach.
• Digital Marketing Momentum: Since launching its social media marketing in April 2026, CompuFlo^® social media content has generated more than 217,000 views and approximately 1,600 link clicks through October 27, 2026, expanding awareness among potential customers and supporting physician outreach and lead generation.
• Major Healthcare Network Opportunities: Milestone’s development relationship with Pain and Spine Specialists, led by Dr. Sudhir Rao, spans 22 locations across four states. Additional commercial engagement includes Rothman Orthopaedics, Main Line Health and Memorial Health, representing prospective institutional opportunities at varying stages.
• Growing Physician Adoption: The CompuFlo Advisor Program has generated more than 200 procedure-feedback submissions across approximately 15 sites, supporting clinical experience, physician advocacy and reimbursement development.
• Established Medicare Payment Pathways: Approximately $325 per qualifying CPT^® 0777T procedure has been reported in Novitas and First Coast jurisdictions, with Avania Medical LLC supporting broader reimbursement and market-access initiatives.
• Expanded U.S. Commercial Organization: Five dedicated medical sales professionals, approximately 15 sales consultants, three distribution partners, and additional clinical, reimbursement and physician-advisor resources support market penetration.
• Federal Healthcare Expansion: Strategic distribution partner Red One Medical provides access to VA, Department of Defense, Defense Health Agency and other federal healthcare customers, supporting potential nationwide institutional adoption.
• Growing International Footprint: Clinical education initiatives in Italy reached more than 40 physicians from over 10 hospitals, while relationships with Movi S.p.A. in Italy, Avalon Medical in Qatar and Luxxustone Spa in Chile support broader international expansion.
• Extensive Global Intellectual Property: Approximately 305 issued patents, including approximately 121 CompuFlo-related patents, together with regulatory approvals in 30 countries, support the Company’s technology platform and potential future applications.
• Expanding Clinical Evidence: CompuFlo has been evaluated or utilized at more than 40 universities, academic medical centers and teaching hospitals worldwide, with additional clinical research and academic collaborations underway.

Large Market Opportunity and Recurring Revenue Potential

Milestone believes CompuFlo’s commercial opportunity is supported by the scale of the global epidural market and its recurring-use business model.

Each additional active physician and procedure creates potential demand for the Company’s proprietary disposable products, providing an opportunity to build predictable purchasing patterns as clinical adoption expands.

The Company’s commercial strategy focuses on converting physician interest into active accounts through demonstrations, training, initial procedures, reimbursement support and repeat purchasing.

Milestone believes larger multisite physician practices and healthcare systems provide particularly attractive opportunities, as initial successful adoption may enable expansion across additional physicians and affiliated locations.

Building the Foundation for Broader Market Penetration

Milestone is executing a targeted geographic strategy, initially concentrating commercial resources in Medicare jurisdictions with established payment pathways and expanding into additional regions as physician utilization and reimbursement experience develop.

The Company is increasing its visibility through leading pain and neuromodulation conferences, including ASPN, FSIPP and ISPN, together with physician webinars, hands-on education and engagement with key opinion leaders.

Clinical validation remains a central component of this strategy. A recent 79-patient peer-reviewed University of Texas Medical Branch study associated CompuFlo-guided epidural access during spinal cord stimulator implantation with approximately 91% lower adjusted odds of composite complications compared with conventional loss-of-resistance techniques.

Additional research, including a University of Minnesota evaluation of CathCheck^®, is intended to support broader clinical understanding and utilization across appropriate epidural applications.

Milestone also intends to leverage its broad intellectual-property portfolio to explore additional applications of Dynamic Pressure Sensing^® technology beyond the current epidural market.

Management Commentary

Eric Hines, Chief Executive Officer of Milestone Scientific, commented:

“We believe Milestone is entering an important new phase of commercial growth. We are addressing a large global market with patented technology, growing clinical validation, established reimbursement pathways and a significantly expanded commercial organization.

“The scale of the opportunity is compelling. Just 2% penetration of the estimated U.S. procedure market represents approximately $33 million in potential annual disposable revenue at our illustrative selling-price assumption, before considering international expansion, equipment sales or additional medical applications.

“Our commercial strategy is now focused on converting our growing pipeline of more than 500 U.S. opportunities into active accounts, increasing procedure volumes and expanding successful adoption across larger healthcare networks.

“With growing physician utilization, federal market access, expanding international distribution and a substantial global patent portfolio, we believe the Company has established a stronger foundation for long-term growth.

“Our goal is to scale recurring disposable revenue, replicate successful commercialization across additional markets and continue advancing the clinical and utilization evidence necessary to pursue CPT Category I status, supporting broader adoption of CompuFlo.”

About Milestone Scientific Inc.

Milestone Scientific Inc. is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology^® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2025. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:

HAYDEN IR:

James Carbonara

(646)-755-7412

james@haydenir.com

Brett Maas

(646) 536-7331

brett@haydenir.com

ASHBURN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 5, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from the third quarter of 2026.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009 that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit www.quoinpharma.com or LinkedIn for updates.

For further information, contact:

Quoin Pharmaceuticals Ltd.
Dr. Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com

Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341